Ignet

Gene Information

Gene symbol: LYVE1

Gene name: lymphatic vessel endothelial hyaluronan receptor 1

HGNC ID: 14687

Synonyms: LYVE-1

Related Genes

#	Gene Symbol	Number of hits
1	CCL21	1 hits
2	CD34	1 hits
3	CD44	1 hits
4	CSF1	1 hits
5	FGF23	1 hits
6	FIGF	1 hits
7	FLT4	1 hits
8	IGF1	1 hits
9	INS	1 hits
10	NUDT6	1 hits
11	PDPN	1 hits
12	PECAM1	1 hits
13	VEGFA	1 hits
14	VEGFC	1 hits

Related Sentences

#	PMID	Sentence
1	11596156	These are VEGF-C, VEGF-D, VEGFR-3, LYVE-1, podoplanin, and Prox-1.
2	11596156	Monoclonal antibodies raised against VEGFR-3 and against its ligands, VEGF-C and VEGF-D, have offered an insight into expression studies in tissues.
3	15181073	Using immunohistochemistry for CD34, LYVE-1 (specific markers for vascular and lymphatic endothelium, respectively), vascular endothelial growth factor (VEGF)-A, VEGF-C, and fibroblast growth factor (FGF)-2, this study analyzes microvascular density (MVD), lymphatic vascular density (LVD), and expression of angiogenic and lymphangiogenic growth factors in 13 normal PTG, 77 parathyroid adenomas (PTA), and 17 primary parathyroid hyperplasia (PPH).
4	15181073	MVD was higher in PPH and PTA, compared with PTG (P < 0.001).
5	15736104	Effects of insulin, glucose, IGF-I, or growth hormone on human arterial smooth muscle cells.
6	15736104	The objective of this study was to examine the influence of glucose, insulin, insulin-like growth factor I (IGF-I), and human growth hormone (hGH) on the formation and function of the HA receptor CD44 in cultures of human aortic smooth muscle cells (SMCs).
7	15736104	The migration assay showed that glucose, insulin, and IGF-I were able to stimulate SMC migration (2 P < .01).
8	15736104	CD44 expression was only elevated at 1000 micro U/mL insulin (2 P < .03), whereas CD44 content decreased at 2 ng/mL hGH and increased at 16 ng/mL hGH (2 P < .01).
9	15736104	Glucose and IGF-I reduced the amount of the variant isoform CD44v3 (2 P < .01) but did not change the amount of total CD44.
10	17176958	Thymic lymphatic endothelial cells showed suggestive expression patterns of the functional molecules lymphatic vascular endothelial hyaluronan receptor (LYVE)-1, CCL21, CD31 and podoplanin.
11	17176958	The CD4- and CD8-positive T cells frequently penetrated through the slender lymphatic walls.
12	17392158	We now demonstrate that this is a general phenomenon; cells that co-stain for the macrophage marker F4/80 and the lymphatic markers LYVE-1 (lymphatic vascular endothelium hyaluronate receptor) and podoplanin contribute to lymphatic vessels in full-thickness wounds.
13	17392158	Glucose treatment of control macrophages led to the down-regulation of the lymphatic-specific receptor VEGFR3 and its ligands, vascular endothelial growth factor-C and -D (VEGF-C, -D).
14	18205092	Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
15	18205092	The angiogenic growth factor Vascular Endothelial Growth Factor-C (VEGF-C) and its receptor VEGFR-3 are also known to be implicated in the development of lymphatic vessels.
16	18205092	We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections.
17	18205092	VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3.
18	18205092	Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary.
19	18205092	Most of the tumours positive for VEGFR-3 did not show any LYVE-1 positive vessels (18/53), suggesting that at least in these cases, VEGFR-3 is expressed on blood vessels.
20	18205092	In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.
21	18230836	Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
22	18230836	Here, we demonstrate the roles of serum FGF23 and 1,25(OH)2D3, together with the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), as biomarkers for OOM.
23	18230836	Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
24	18230836	Here, we demonstrate the roles of serum FGF23 and 1,25(OH)2D3, together with the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), as biomarkers for OOM.
25	19248616	[Hyaluronic acid, receptor CD44, and their role in diabetic complications].
26	19248616	The most important member of the Link module superfamily is the main HA receptor, CD44.
27	19248616	[Hyaluronic acid, receptor CD44, and their role in diabetic complications].
28	19248616	The most important member of the Link module superfamily is the main HA receptor, CD44.
29	19398755	We used osteopetrotic (op/op) mice to demonstrate that M-CSF deficiency reduces the abundance of LYVE-1(+) and LYVE1(-) macrophages, resulting in defects in vascular and lymphatic development.
30	19398755	In contrast to VEGF blockade, interruption of M-CSF inhibition did not promote rapid vascular regrowth.